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Objectives. We sought to serially assess left ventricular (LV)
function before and after catheter ablation of atrial flutter (AFl).
Background. The relation of tachycardia-induced cardiomyop-
athy to AFl and its response to direct catheter ablation are
unknown.
Methods. LV function was assessed in a series of 59 consecutive
patients with successful radiofrequency ablation (RFA) of AFl
before and after the procedure. Eleven patients had dilated
cardiomyopathy (LV ejection fraction [LVEF] <50%) and conges-
tive heart failure (CHF) symptoms and are the subject of this
report. LV function was assessed by LVEF on two-dimensional
echocardiography and functional status by New York Heart
Association (NYHA) CHF classification.
Results. Patients were 59 6 8 years old, and were all male. Five
patients had a preablation diagnosis of idiopathic cardiomyopa-
thy. The preablation LVEF was 30.9 6 11.0% and improved to
41.3 6 16% (p 5 0.005) when measured 7 months after successful
ablation. NYHA CHF class improved from 2.6 6 0.5 to 1.6 6 0.9
(p 5 0.002). Six (55%) of 11 patients had normalization of the
LVEF, with complete resolution of CHF symptoms. A lower
preablation LVEF and functional class predicted nonresolution of
dilated cardiomyopathy (p 5 0.002 and 0.001, respectively).
Conclusions. Restoration of normal sinus rhythm by RFA in
patients with chronic AFl and cardiomyopathy substantially im-
proved LV function. Resolution of dilated cardiomyopathy oc-
curred in the majority of patients. Tachycardia-induced cardio-
myopathy may be a more common mechanism of LV dysfunction
in patients with AFl than expected, and aggressive treatment of
this arrhythmia should be considered.
(J Am Coll Cardiol 1998;32:205–10)
©1998 by the American College of Cardiology
Tachycardia-induced cardiomyopathy has been described as a
distinct clinical entity and has been referred to as the most
frequently unrecognized curable cause of heart failure (1).
Timely recognition and correct diagnosis can lead to improve-
ment in ventricular function, relief of congestive heart failure
(CHF) and, usually, cure if effective rate slowing measures are
undertaken. Animal models of tachycardia-induced cardiomy-
opathy demonstrate impaired systolic and diastolic function,
reduced response to catecholamine stimulation and defective
myocyte contractile function; all may improve after control of
tachycardia (2–4). There are numerous case reports and small
series describing reversal or improvement of dilated cardiomy-
opathy after control of ventricular response in a variety of
supraventricular and ventricular tachycardias in adults and
children by pharmacologic, surgical and, more recently, trans-
venous catheter ablation techniques (5–16). Control of tachy-
cardia has been achieved by permanently reducing ventricular
conduction or by sustained restoration of normal sinus rhythm
(NSR).
Recently, radiofrequency catheter ablation of common
atrial flutter (AFl) has been described as a safe and effective
means of cure of refractory AFl, with good long-term out-
comes in several series (17–21). In the present series,
prompted by a previous observation (21), we investigated the
contribution of persistent AFl to the development of left
ventricular (LV) dysfunction and the evolution of tachycardia-
induced dilated cardiomyopathy in a group of patients under-
going successful radiofrequency ablation (RFA) of AFl. At the
time of referral, this group of patients was presumed to have
AFl secondary to structural heart disease. The results of our
study suggest that in these patients a tachycardia-induced
mechanism was the cause of, or contributed to, LV dysfunc-
tion.
Methods
Patient selection. Patients with refractory type 1 (common)
AFl were referred for RFA as definitive treatment. Refractory
AFl was defined as the failure of more than two cardioversions
and more than two antiarrhythmic medications to maintain
NSR. All patients had electrocardiographically documented
type 1 AFl, defined as inverted P waves (sawtooth pattern) in
leads II, III, aVF and upright P waves in lead V1. Patients were
specifically excluded for the presence of, or history of, docu-
mented atrial fibrillation.
RFA. All patients gave written informed consent for the
ablation procedure. Antiarrhythmic medications were withheld
for at least 7 days before RFA. RFA was performed according
to an anatomically guided approach, as published previously
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(18,21). Patients were in the fasting state and received mida-
zolam and fentanyl for sedation.
Patient follow-up. Patients with successful RFA were dis-
charged without administration of any antiarrhythmic medica-
tion. They were examined as outpatients after 3 to 4 weeks and
every 3 months thereafter. Any symptoms suggestive of ar-
rhythmia were investigated with an electrocardiogram (ECG),
24-h Holter ECG recording or transtelephonic ECG event
recording. Patients were treated with aspirin (325 mg daily) for
3 months as prophylaxis against thromboembolic events.
LV function assessment. LV function was assessed by
visual estimation of LV ejection fraction (LVEF) with two-
dimensional echocardiography in all patients, measurement of
end-diastolic and end-systolic LV volumes and fractional
shortening before and after the ablation procedure. Two-
dimensional echocardiography has been shown (22–24) to be a
valid and reliable method of measuring LV function. The
echocardiograms were obtained in the days preceding the
ablation procedure and again 7 months (median) after the
successful ablation. Echocardiograms were acquired at the
ablation center or at the referring hospital if the patient was
from a geographically distant site. Echocardiographers were
unaware of the patient’s ablation status. In addition, assess-
ment of clinical functional status and use of medications to
combat CHF were noted.
Statistics. Results are reported as mean value 6 SD. The
paired Student t test was used to compare variables before and
after RFA. Clinical characteristics of patients with versus those
without improvement in LV function were compared using
unpaired Student t test. The Fisher exact test was used for
analysis of categoric variables as predictors of end points.
Results
Patient characteristics. In our laboratory, 59 of 61 patients
underwent successful RFA of AFl. Eleven patients had an
LVEF ,50% before ablation (all successful) and are the
subjects of the present report. All 11 patients were male and
were of 59 6 8 years old. The duration of AFl before ablation
was 13 6 5 months (range 6 to 24), and all patients had chronic
AFl. Ventricular rates .100 beats/min had been present in all
patients, with a mean heart rate before ablation of 102.3 6 24.7
beats/min. All patients had symptoms of LV dysfunction. Mean
New York Heart Association (NYHA) CHF class before
ablation was 2.6 6 0.5, and LVEF was 30.9 6 11.0%.
All patients were described by the referring physicians as
having cardiovascular disease; two patients had a history of
hypertension; three had a history of myocardial infarction, two
of whom also had a history of hypertension; and one patient
had previously undergone aortic valve replacement for aortic
stenosis. Five patients were diagnosed as having idiopathic
dilated cardiomyopathy on the basis of the presence of signif-
icant LV dysfunction without the presence of an identifiable
etiology (e.g., coronary artery disease, hypertension, valvular
heart disease, alcohol abuse) (25). In all patients, the AFl was
believed to have resulted from the underlying cardiovascular
disease and cardiomyopathy.
Follow-up of LV function after ablation. All patients re-
mained in NSR during the follow-up period of 35.5 6 10.4
months, without the need for antiarrhythmic treatment or a
repeat ablation procedure. They were followed up by both the
arrhythmia service and the referring physicians, and NSR was
present at each visit, without reports of clinically recognizable
AFl. After successful RFA, LVEF increased from 30.9 6
11.0% to 41.4 6 16.3% (p 5 0.005). Heart rate decreased from
102.3 6 24.7 to 78.7 6 10.7 beats/min (p 5 0.005). Figure 1
contrasts LVEF before and after ablation in the individual
patients. Table 1 shows the differences in clinical characteris-
tics before and after ablation. The overall improvement in
LVEF correlated with the change in systolic LV dimensions.
LV end-systolic dimension decreased from 4.8 6 1.4 to 4.0 6
1.3 cm (p 5 0.03) and LV end-diastolic dimension from 5.8 6
1.0 to 5.7 6 0.7 cm (p 5 NS). Fractional shortening increased
from 18.7 6 10.1% before to 31.3 6 14.4% after ablation (p 5
0.001). There was no significant difference in LV wall thickness
before and after ablation. Symptoms of CHF significantly
decreased during follow-up as well. NYHA CHF class de-
creased from 2.6 6 0.5 before to 1.6 6 0.9 after ablation (p 5
0.002).
Eight (73%) of the 11 patients showed an absolute improve-
Abbreviations and Acronyms
ACE 5 angiotensin-converting enzyme
AFl 5 atrial flutter
AV 5 atrioventricular
CHF 5 congestive heart failure
ECG 5 electrocardiogram, electrocardiographic
LV 5 left ventricular
LVEF 5 left ventricular ejection fraction
NYHA 5 New York Heart Association
NSR 5 normal sinus rhythm
RFA 5 radiofrequency ablation
Figure 1. Comparison of LVEF before and after RFA. Mean LVEF
improved from 30.9 6 11% to 41.4 6 16%.
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ment in LVEF of at least 5%. When the clinical characteristics
of the eight patients who showed improvement in LVEF were
compared with those of the three who did not, no statistically
significant difference was found in age and duration of AFl.
However, there was a statistically significant difference in
LVEF and NYHA CHF class before ablation between the two
patient groups: Patients who did not improve had a signifi-
cantly worse LVEF (20.3 6 0.6% vs. 34.9 6 1.7%, p 5 0.048)
and CHF class (3.0 6 0.0 vs. 2.3 6 0.5, p 5 0.024) before
ablation. Of the patients who improved, two patients had
hypertension, and two had hypertension and a previous myo-
cardial infarction; the remaining four had no history of cardio-
vascular disease other than idiopathic cardiomyopathy. In the
three patients who did not improve, one had a history of
myocardial infarction, one had a history of aortic valve replace-
ment, and the third had no known cardiovascular history other
than idiopathic cardiomyopathy.
Before RFA, most patients had severe LV dysfunction and
55% of the study group had an LVEF ,30%. Figure 2
contrasts the distribution of LVEF before and after ablation.
After ablation, only 3 patients (27%) had an LVEF .30%, and
strikingly, 6 (55%) had an LVEF $50%. In other words,
LVEF improved in the majority of patients to within the
normal range after ablation.
Resolution of dilated cardiomyopathy. Of the 11 patients
in the present series, 6 (55%) had complete normalization of
LV function, with an LVEF .50% after ablation. The absolute
improvement in LVEF in this group was 17.8%. All patients
reported improvement in functional capacity and complete
resolution of CHF symptoms; medications for CHF were
discontinued in all patients by their primary physicians. A
detailed analysis was undertaken to identify the patient char-
acteristics that were associated with normalization of LV
function. There was no difference in age or AFl duration
between the patients who showed normalization and those who
did not. However, there was a statistically significant difference
between the two groups in LVEF and NYHA CHF class. The
preablation LVEF was 39.0 6 8.7% in the group with resolu-
tion and 21.2 6 2.2% in the group without normalization (p 5
0.002). NYHA CHF class was 2.2 6 0.4 in the former group
and 3.0 6 0.0 in the latter (p 5 0.001).
The relation of preablation diagnosis to resolution of
cardiomyopathy showed that four (66%) of six patients in the
group with normalization had a preablation diagnosis of
idiopathic dilated cardiomyopathy compared with only one
(20%) of five in the group without normalization (p 5 NS,
Fisher exact test). Of the patients in the group with normal-
ization and no diagnosis of idiopathic cardiomyopathy, one
had a history of hypertension, and another had a history of
inferior wall myocardial infarction and hypertension.
Of the six patients who showed resolution of cardiomyop-
athy, five were taking digoxin, one quinidine, two procain-
amide, one flecainide and two amiodarone (all drugs were
discontinued before echocardiography and ablation, according
to procedure protocol). All six patients were taking angiotensin-
converting enzyme (ACE) inhibitors before RFA. After abla-
tion, quinidine, procainamide, amiodarone and digoxin were
not restarted in those six patients. Of the five patients without
resolution of cardiomyopathy, all were receiving digoxin and
ACE inhibitors before ablation. One patient was taking fle-
cainide and amiodarone and another amiodarone alone. An-
tiarrhythmic agents were not restarted after ablation. There
were no patients taking beta-adrenergic blocking agents before
or after ablation. One patient was taking amlodipine before
ablation and also received this medication afterward. No other
calcium channel blocking agents were used by any patient.
Discussion
In the present series of patients undergoing RFA for AFl
we demonstrated 1) an overall improvement in LVEF, with
restoration of NSR; 2) resolution of dilated cardiomyopathy in
a significant subset of these patients; and 3) a decreased
likelihood of resolution of dilated cardiomyopathy when the
preablation LV dysfunction and clinical status were more
Table 1. Clinical Characteristics Before and After Ablation for
Atrial Flutter
Before RFA After RFA
p
Value
Heart rate (beats/min) 102.3 6 24.7 78.7 6 10.8 0.005
NYHA CHF class 2.6 6 0.5 1.6 6 0.9 0.002
LVEF (%) 30.9 6 11.0 41.4 6 16.3 0.005
LV ED dimensions (cm) 5.8 6 1.0 5.7 6 0.7 NS
LV ES dimensions (cm) 4.8 6 1.4 4.0 6 1.3 0.03
Fractional shortening (%) 18.7 6 10.1 31.3 6 14.4 0.001
LV wall thickness (cm) 1.3 6 0.1 1.3 6 0.2 NS
Data presented are mean value 6 SD. CHF 5 congestive heart failure;
ED 5 end-diastolic; ES 5 end-systolic; LV 5 left ventricular; LVEF 5 left
ventricular ejection fraction; NYHA 5 New York Heart Association; RFA 5
radiofrequency ablation.
Figure 2. Change in distribution of LVEF after RFA for AFl. Six of 11
patients had normalized LVEF after RFA.
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severe. It is generally believed that chronic or persistent AFl
occurs in the setting of organic heart disease, often valvular,
ischemic or dilated cardiomyopathy (26,27), rather than in the
absence of heart disease. In addition, it is believed that most
AFl tends to be unstable, degenerating to atrial fibrillation or
reverting to NSR (26,27). When AFl is recurrent or chronic,
especially if antiarrhythmic drugs have failed to reestablish
NSR, ventricular rate control is usually attempted. However,
pharmacologic control of rate is very difficult to achieve,
especially on a consistent basis. The belief that AFl occurs in
the setting of cardiomyopathy, that it may ultimately transform
to atrial fibrillation and the frequent difficulty in achieving
effective rate control set up conditions ripe for the develop-
ment of unrecognized tachycardia-induced cardiomyopathy in
patients with chronic AFl. The present series, and a previous
description of a single case of ours (21), represent the first
report of resolution of tachycardia-induced cardiomyopathy by
RFA for AFl.
Tachycardia-induced cardiomyopathy. Early reports in the
first half of this century showed cardiac enlargement and CHF
after onset of atrial fibrillation and resolution by pharmaco-
logic cardioversion or rate control (28,29). These observations
suggested tachycardia as the etiologic factor for cardiomyopa-
thy, especially when other causes for CHF could not be found.
Subsequent series of patients have shown improvement in
LVEF after control of ventricular rates in different types of
tachycardia, further reinforcing the concept of tachycardia-
induced cardiomyopathy as a clinical entity. For example,
improvement in LVEF was observed after control of tachycar-
dia in a series of eight patients with ectopic atrial tachycardia
or accessory atrioventricular (AV) pathway after His bundle
and AV node ablation (13), 10 patients with atrial fibrillation
after RFA of the His bundle (14) and a series of 10 patients
with atrial fibrillation after different means of rate control (15).
In animal models, dilated cardiomyopathy is produced by
inducing tachycardia through chronic electronic pacing. After
cessation of tachycardia, LV function normalizes along with
the animals’ neurohormonal profile, although decreased LV
mass and myocyte contractile function may persist (2–4). In
humans, the diagnosis of tachycardia-induced cardiomyopathy
can only be made in retrospect, making clinical features that
predict this diagnosis very important. A recent review (1)
suggested a set of simple clinical characteristics that should
raise the suspicion of tachycardia-induced cardiomyopathy: 1)
dilation of the heart or clinical heart failure, and 2) chronic or
very frequent cardiac arrhythmias. The group of patients
studied in the present report fulfill both criteria.
AFl as a cause of tachycardia-induced cardiomyopathy. All
patients who had resolution of cardiomyopathy in the present
report were referred with a diagnosis of AFl caused by the
dilated cardiomyopathy. The objective of treatment was to
control the rapid ventricular rates generated by refractory AFl
and alleviate tachycardia symptoms and CHF. The finding of
improvement in LVEF in a substantial segment of the series
was unanticipated. One patient with a diagnosis of idiopathic
dilated cardiomyopathy did not improve and had an LVEF of
20%. This lack of improvement may have reflected irreversible
myocardial damage not amenable to improvement or cure with
ablation, despite the presence of tachycardia as a potential
explanation for dilated cardiomyopathy (1), and is further
supported by the findings of the comparison of clinical char-
acteristics between those patients who showed improvement
and those who did not. This comparison showed that the latter
group had a lower preablation LVEF and a poorer functional
status as measured by NYHA CHF class, further suggesting
that in this group of patients, the cardiomyopathy may not be
amenable to improvement because of irreversible structural
changes that correlate with worse LVEF and functional status.
Furthermore, the comparison between the group with and that
without resolution of cardiomyopathy again showed a lower
LVEF and worse functional status as negative predictors for
resolution of cardiomyopathy. These findings may be explained
by a disruption in myocardial architecture produced by tachy-
cardia that could result in scarring and therefore irreversible
myocardial damage, as seen in animal models of tachycardia-
induced cardiomyopathy (4,30). This hypothesis suggests the
importance of early detection of chronic AFl and institution of
effective rate control measures to prevent permanent damage.
Most patients with normalization of LV function had a pre-
ablation diagnosis of idiopathic dilated cardiomyopathy, but
this variable failed to meet statistical significance as an indica-
tor of resolution of cardiomyopathy. Because the number of
patients in this group was small, it would be ideal to assess this
relation in a larger series.
One patient with a history of hypertension, but not coronary
artery disease, myocardial infarction or valvular heart disease,
had resolution of cardiomyopathy after ablation, which sug-
gests that the tachycardia was the main mechanism for ven-
tricular dysfunction rather than chronic hypertension. Another
patient with hypertension and a history of an inferior wall
myocardial infarction also showed resolution of dilated cardio-
myopathy, also suggesting tachycardia-induced cardiomyopa-
thy as the main mechanism for ventricular dysfunction. The
echocardiogram in this patient showed global hypokinesia
before ablation, with an LVEF of 35%; the postablation
echocardiogram showed only inferior wall hypokinesia and an
LVEF of 50%, supporting the assertion that the inferior wall
myocardial infarction was not the main etiology of the LV
dysfunction. These observations suggest that tachycardia
should be considered a possible underlying cause of dilated
cardiomyopathy in those patients with ventricular dysfunction
or a ventricular motion pattern, out of proportion to the
underlying anatomic substrate. A recent review of tachycardia-
induced cardiomyopathy (1) introduced the concept of pure
and impure tachycardia-induced cardiomyopathy, the former
existing in those cases in which the tachycardia is the sole
explanation for the ventricular dysfunction and the latter
occurring in cases in which other factors may contribute to the
reduction in LVEF. The patients in our series who showed
improvement in LV function without achieving normalization
and had a diagnosis other than idiopathic dilated cardiomyop-
athy could be classified as having impure tachycardia-induced
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cardiomyopathy, and all those with normalized ventricular
function could be classified as having pure tachycardia-induced
cardiomyopathy, even the patient with a history of hyperten-
sion because the latter diagnosis probably had no bearing on
the preablation LV dysfunction. The example mentioned
previously stresses the need to consider correction of the arrhyth-
mias, even in the presence of seemingly logical causes for
cardiomyopathy, because of the possibility of several simulta-
neous underlying mechanisms of dilated cardiomyopathy.
Other therapeutic options exist for the treatment of AFl,
but all have drawbacks. Control of ventricular response by
pharmacologic means could help to improve LV function, but
this goal is often not achieved. Some medications can also
reduce LV function. AV junction ablation will permanently
eliminate rapid rates but does not restore AV synchrony or
normal chronotropic response and necessitates permanent
pacemaker implantation. Antiarrhythmic therapy can assist in
the maintenance of NSR but can have serious side effects (31).
Limitations of the study. The small number of patients in
the present series and the referral bias for RFA precludes
determining the true prevalence of dilated cardiomyopathy
secondary to AFl. Echocardiography was not uniformly per-
formed at a single laboratory, but all measurements were
performed in a similar manner. In addition, most of the
echocardiograms were rereviewed by a single observer, and the
results were confirmed. Visual estimation of LVEF has been
proven to be a highly accurate and reproducible measure of
LV function (22–24) and correlates well with findings in gated
nuclear angiography, contrast ventriculography and sophisti-
cated computer techniques. The fractional shortening calcula-
tions confirm the study observations. Assessment of LV func-
tion was performed only once before the procedure and once
after the procedure. Ideally, echocardiography would be per-
formed serially after the procedure because previous studies
indicate that recovery can occur late, especially in patients with
more severe dysfunction (1). No postablation invasive studies
were available to correlate hemodynamic variables with the
LVEF findings in the present series.
Conclusions. In patients with both AFl and LV dysfunc-
tion, tachycardia may play a primary rather than secondary
role. Given the prevalence of AFl relative to other incessant or
chronic tachycardias, AFl may be a common etiology of
tachycardia-induced cardiomyopathy. Cure or control of AFl
should be seriously considered in all patients with the uncon-
trolled form of AFl, with or without LV dysfunction, to prevent
or improve cardiomyopathy. Further studies are needed to
assess the scope of this condition.
ADDENDUM. Since submission of the manuscript for this
report, one additional patient with AFl of 9 months in duration
and an LVEF of 20% underwent successful ablation. Six weeks
after ablation the LVEF was 55%.
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